We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Molecular Computers May Let Patients Diagnose and Treat Themselves

By Biotechdaily staff writers
Posted on 12 May 2004
A microscopic computer constructed from a portion of a DNA molecule has been successfully tested in vitro, suggesting that such a device might someday be able to detect the presence of a disease in an individual and then produce a drug molecule to combat it.

Investigators at the Weizmann Institute of Science (Rehovot, Israel; www.weizmann.ac.il) developed the molecular computing device, which is so small that nearly a trillion of them can be contained in 1 ml of liquid. More...
The molecular computing device belongs to the class of finite computers, which is a simplified version of the Turing machine, a mathematical model of computation developed by the British mathematician Alan Turing in the 1930s. As such, the molecular computer has three components: an input molecule, which stores the data to be processed as well as the fuel needed for the computation; software molecules, which encode program rules; and a hardware molecule that performs the computation, as directed by the software and the input. The molecules are suspended in a saline solution needed for the operation of the hardware molecule.

Details of the molecular computer were published April 28, 2004, in the online edition of Nature. They revealed that the input molecule is a double-stranded DNA molecule with a "sticky-end” single-stranded protrusion obtained by having one strand longer than the other. The software DNA molecules also have "sticky-ends,” each matching a different input combination. Through spontaneous DNA hybridization the input molecule and a matching software molecule temporarily bind to each other.

The hardware is an enzyme called FokI that attaches to DNA in a specifically coded location and cuts both strands at a fixed distance from that location, creating a sticky end. By employing additional chemical and mathematical tricks, the software molecules can be designed so that the hardware enzyme attaches to them and, once a software molecule hybridizes with an input molecule, the hardware enzyme cuts the input molecule in a programmed location, exposing a new sticky end that encodes the next state to be processed. The final sticky end, obtained at the end of the computation, encodes the computation result.

A unique property of the design of the molecular computer is that the DNA input molecule is also the source of the power that runs the computer. The energy is inherent to the chemical structure of DNA and is independent of the actual data it encodes, but is dependent on the length of the molecule.

Each molecular computer is rather slow. On average, it performs one operation per 20 seconds. On the other hand a 5 ml spoonful of these computers would be able to perform nearly 330 trillion operations per second, which is more than 100,000 times faster than the fastest personal computer, with an energy efficiency more than a million times that of a personal computer.

To demonstrate that the device actually works, the investigators successfully programmed the computer to identify and analyze mRNA of disease-related genes associated with models of small-cell lung cancer and prostate cancer, and to produce a single-stranded DNA molecule modeled after an anticancer drug.

Senior author Dr. Ehud Shapiro, a professor in the departments of computer sciences and applied mathematics at the Weizmann Institute said, "It is clear that the road to realizing our vision is a long one; it may take decades before such a system operating inside the human body becomes reality. Nevertheless, only two years ago we predicted that it would take another 10 years to reach the point we have reached today.”




Related Links:
Weizmann Institute of Science

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.